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Abstract: Staphylococcus aureus is one of the most common pathogens that infects the airways of 
patients with cystic fibrosis (CF) and contributes to respiratory failure. Recently, livestock-
associated methicillin-resistant S. aureus (LA-MRSA), usually cultured in farm animals, were 
detected in CF airways. Although some of these strains are able to establish severe infections in 
humans, there is limited knowledge about the role of LA-MRSA virulence in CF lung disease. To 
address this issue, we analyzed LA-MRSA, hospital-associated (HA-) MRSA and methicillin-
susceptible S. aureus (MSSA) clinical isolates recovered early in the course of airway infection and 
several years after persistence in this hostile environment from pulmonary specimens of nine CF 
patients regarding important virulence traits such as their hemolytic activity, biofilm formation, 
invasion in airway epithelial cells, cytotoxicity, and antibiotic susceptibility. We detected that CF 
LA-MRSA isolates were resistant to tetracycline, more hemolytic and cytotoxic than HA-MRSA, and 
more invasive than MSSA. Despite the residence in the animal host, LA-MRSA still represent a 
serious threat to humans, as such clones possess a virulence potential similar or even higher than 
that of HA-MRSA. Furthermore, we confirmed that S. aureus individually adapts to the airways of 
CF patients, which eventually impedes the success of antistaphylococcal therapy of airway 
infections in CF. 
Keywords: LA-, HA-MRSA; MSSA; cystic fibrosis; virulence; hemolysis; biofilm; invasion; 
cytotoxicity 
Key Contribution: LA-MRSA isolated from the airways of CF patients possess a higher virulence 
potential compared to that of CF HA-MRSA in in vitro experiments, which should be taken into 
account for successful antistaphylococcal therapy of CF airway infections. 
 
1. Introduction 
Staphylococcus aureus is one of the most common pathogens which infects and persists in the 
airways of cystic fibrosis (CF) patients [1,2]. CF is a multi-systemic, hereditary disease caused by 
mutations in the CF transmembrane conductance regulator gene that impair ion and water transport 
across epithelial membranes [3]. Consequently, patients with CF suffer from airway dehydration, 
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mucus accumulation, and a dysregulated immune system [4], resulting in bacterial airway infections 
[1] that cause a decline in lung function [5] and reduced life expectancy [6]. Therefore, one of the 
pillars of CF therapy is the antibiotic treatment of bacterial airway infections [7]. Due to the extensive 
application of β-lactam antibiotics in the past, methicillin-resistant S. aureus (MRSA) emerged in 
healthcare settings and the healthy community. Currently, these so-called hospital-associated (HA-) 
and community-associated (CA-) MRSA represent an enormous threat, as they are highly virulent 
and difficult to eradicate [8,9]. Animals from livestock farms can be colonized or infected by MRSA 
[10]. These livestock-associated (LA-) MRSA, which most likely were derived from human 
methicillin-susceptible S. aureus (MSSA) [10], predominantly colonize animal hosts, but can be 
transferred back and may provoke severe diseases in humans [11,12]. LA-MRSA are a distinct 
subgroup of MRSA predominantly associated with the multilocus sequence typing (MLST) clonal 
complex (CC) 398 and harbor staphylococcal protein A gene (spa)-types t011, t034, t108, and close 
relatives. Another feature of LA-MRSA is the carriage of the resistance gene tetM, which confers 
resistance against tetracycline [10]. Numerous virulence factors enable S. aureus to induce and sustain 
long-term infections in humans and animals. Adhesins, located on the bacterial cell surface, interact 
with plasma proteins or extracellular matrix components of the host and facilitate bacterial adhesion 
[13]. Subsequently, bacterial proliferation, systemic spread, and toxinosis are provoked by 
hemolysins, leukocidins, exotoxins, enterotoxins, and proteases that lyse host cells, degrade tissue, 
and contribute to nutrient acquisition [14]. S. aureus possesses α-, β-, γ-, and δ-hemolysins that are 
under the control of the accessory gene regulator (agr) and predominantly lyse erythrocytes by either 
forming pores in the host cell membranes or degrading cell wall components [15,16]. In addition, S. 
aureus is able to hide from the host immune system by expressing immunomodulatory factors, like 
chps (chemotaxis inhibitory protein of S. aureus) and scin (staphylococcal complement inhibitor), 
located on bacteriophages [17]. Additionally, the formation of biofilms, which are multicellular 
agglomerations embedded in a matrix formed by proteins, polysaccharides, and/or extracellular 
DNA [18], supports bacterial immune evasion and presents an adaptation advantage during 
staphylococcal persistence in CF airways [19]. Furthermore, the bacterial invasion of host cells, 
mediated by a number of bacterial adhesion proteins, provides additional protection from the host 
immune system and antibiotic therapy, and is suggested to contribute to recurrent staphylococcal 
infections and long-term persistence in CF patients [20,21]. 
Respiratory infections caused by MRSA are associated with more severe lung disease compared 
to MSSA in CF patients [6]. Quite recently, LA-MRSA were detected in the airways of CF patients 
[22–24]. However, although some studies analyzed the virulence and pathogenicity of LA-MRSA 
recently [25], there is only limited knowledge about the role of LA-MRSA virulence in CF lung 
disease, especially if such LA-MRSA clones persist in the airways for extended periods. Therefore, 
we characterized 18 LA-MRSA, HA-MRSA, and MSSA clinical isolates of nine CF patients, which 
were isolated early in the course of airway infection and several years after persistence in this hostile 
niche. These isolates were analyzed by MLST and spa-genotyping and further characterized 
regarding their hemolytic activity, biofilm formation, invasion in airway epithelial cells, cytotoxicity, 
and antibiotic resistance. We detected that CF LA-MRSA isolates were more hemolytic and cytotoxic 
than HA-MRSA and more invasive than MSSA, indicating that despite their prior residence in the 
animal host, they still have a highly virulent phenotype in humans. 
2. Results 
2.1. LA-MRSA are Strongly Hemolytic 
The hemolysins of S. aureus differ in their affinity to red blood cells of various species. While α-
hemolysin has a high affinity for rabbit erythrocytes, which express high amounts of the α-hemolysin 
receptor ADAM-10 (a disintegrin and metalloprotease 10) on their surface [16], the activity of the 
sphingomyelinase β-hemolysin is more dedicated to the sphingomyelin-rich membrane of sheep 
erythrocytes [26]. To get a broad overview of the hemolytic activity of LA-MRSA, HA-MRSA, and 
MSSA clinical CF isolates, we (a) plated bacterial strains on Columbia sheep blood agar and assessed 
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hemolysis macroscopically after incubation at 37 °C, and subsequently 4 °C, for 24 h, and (b) 
incubated rabbit erythrocytes with bacterial supernatants, measured the absorbance of released 
hemoglobin, and determined the dilution step at which 50% of all erythrocytes were lysed (ED50). In 
addition, a microarray analysis was performed to detect hemolysis-associated virulence genes. After 
incubation at 37 °C on sheep blood agar, all LA-MRSA and most HA-MRSA and MSSA revealed 
narrow to broad zones of clear hemolysis (Table 1, Figure S1), indicative of α-hemolysin production. 
However, only the hemolytic halo of the LA-MRSA strains and the late HA-MRSA isolate t548 was 
surrounded by a large dark, diffuse zone of hemolysis, which became clear after overnight incubation 
at 4 °C (Table 1, Figure S1). This “hot–cold hemolysis” is indicative of β-hemolysin production [16]. 
All isolates that were strongly hemolytic on sheep blood agar had a high ED50 and thus a strong 
hemolytic effect on rabbit erythrocytes in the photometrical quantification assay, except for the late 
MSSA isolate t002 (Figure 1a). Interestingly, two late HA-MRSA isolates (t003 and t548) were 
significantly more hemolytic compared to their corresponding early isolates. Grouping the S. aureus 
isolates according to their agr-type revealed that agrI is the most hemolytic type, followed by agrII 
and agrIII (Figure 1b). Interestingly, while all LA-MRSA and HA-MRSA could be assigned to agrI and 
II, respectively, MSSA belonged to agr-type I, II, and III. Furthermore, the microarray analysis 
revealed that all bacterial strains harbor the genes hla, hld, and hlgA encoding for α-, δ- and γ-
hemolysins, but only the LA-MRSA isolates and the late HA-MRSA isolate t548 carried the intact hlb 
encoding for β-hemolysin (Figure 1c). Importantly, the absence of the intact hlb was accompanied by 
the presence of sak (staphylokinase), chps, and scin (Supplementary Table S1), indicating that hlb was 
interrupted by the integration of a bacteriophage that carries these three immune evasion genes. 
Table 1. Analysis of bacterial hemolysis on Columbia sheep blood agar. Bacteria were streaked onto 
Columbia sheep blood agar and incubated at 37 °C, and subsequently 4 °C, for 24 h, to determine the 
activity of bacterial hemolysins. After incubation at 37 °C, in addition to a clear hemolytic zone, some 
bacterial isolates showed a dark, diffuse zone of hemolysis, which became clear after a 4 °C incubation 
(Figure S1). 
Investigated Bacteria 37 °C Incubation 4 °C Incubation 
Group spa-
type 
Isolate Clear Hemolytic 
Zone 
Dark, Diffuse 
Hemolytic Zone 
Clear Hemolytic 
Zone 
LA-MRSA 
t034S Early + ++++ ++++ 
Late + ++++ ++++ 
t034T Early + ++++ ++++ Late + ++++ ++++ 
t011 
Early + ++++ ++++ 
Late + ++++ ++++ 
HA-MRSA 
t003 Early + - ++ 
Late ++ - ++ 
t010 Early ++ - +++ 
Late ++ - +++ 
t548 
Early - - - 
Late - ++++ ++++ 
MSSA 
t617 
Early + - + 
Late - - + 
t080 Early ++ - +++ 
Late + - ++ 
t002 Early ++ - +++ Late ++ - +++ 
Abbreviations: HA-MRSA (hospital-associated methicillin-resistant S. aureus), LA-MRSA (livestock-
associated methicillin-resistant S. aureus), MSSA (methicillin-susceptible S. aureus), spa 
(staphylococcal protein A), S (isolated from sputum), T (isolated from throat). Symbols: - not 
detectable, + slight intensity, ++ strong intensity, +++ stronger intensity, ++++ very strong intensity. 
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Figure 1. Analysis of the hemolytic effect of supernatants from clinical LA-MRSA, HA-MRSA, and 
MSSA CF isolates on rabbit erythrocytes, according to the spa-type and the agr-type and microarray 
analysis of hemolysis-associated virulence genes. (a + b) Strength of bacterial hemolytic activity was 
determined by incubating rabbit erythrocytes with sterile-filtered supernatants from bacterial 
overnight cultures and measuring the absorbance of released hemoglobin from damaged erythrocytes 
at OD450 nm. Absorbance was plotted against the dilution step. ED50 (the dilution step at which 50% of 
all erythrocytes are lysed) was calculated using the linear slope of the inflection point of the hemolysis 
graph. The higher the ED50, the stronger the hemolytic effect. As a negative control, untreated 
erythrocytes, and as a positive control, erythrocytes treated with Triton X-100, were used. Results 
were grouped according to the spa-type (a) and the agr-type (b) of the clinical isolates. All LA-MRSA 
belonged to agr-type I, all HA-MRSA to agr-type II. MSSA could be divided into agr-type I (spa-type 
t080), agr-type II (spa-type t002), and agr-type III (spa-type t617). (a) Data represent the mean of at least 
four biological replicates ± SD. (b) Biological replicates of the strains grouped according to their agr-
type were averaged and are presented ± SD. Negative values (no hemolysis, no dilution required) 
were set to zero. Statistical analysis was done by applying one-way ANOVA, followed by 
Bonferroni’s post hoc test for multiple comparisons (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). To keep the 
graph clear, only particular significances are displayed. (c) Microarray was performed according to 
the manufacturer’s instructions (Alere Technologies GmbH [now Abbott Rapid Diagnostics GmbH, 
Jena, Germany]). While dark gray squares indicate genes that were detected, white squares mark 
negative results. Light gray squares represent genes whose presence was not determined. 
Abbreviations: agrI/II/III/IV (accessory gene regulator I/II/III/IV), ANOVA (analysis of variance), ED50 
(mean effective dilution), HA-MRSA (hospital-associated methicillin-resistant S. aureus), hla/b/d 
(hemolysin α/β/δ), hlgA (hemolysin γ component A), LA-MRSA (livestock-associated methicillin-
resistant S. aureus), MSSA (methicillin-susceptible S. aureus), NC (negative control), PC (positive 
control), S (isolated from sputum), SD (standard deviation), spa (staphylococcal protein A), T (isolated 
from throat). 
2.2. LA-MRSA are Weak Biofilm Formers 
To assess the biofilm-forming capacity of LA-MRSA, HA-MRSA, and MSSA clinical CF isolates, 
we raised bacterial biofilms in microtiter plates and stained them with crystal violet. In addition, a 
microarray analysis was done to detect biofilm-associated genes. Only the late isolates of LA-MRSA 
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t034T and MSSA t080 formed biofilms when incubated in microtiter plates (Figure 2a), although the 
microarray analysis revealed the presence of icaA, C, and D, which encode for the most common 
staphylococcal biofilm component, polysaccharide intercellular adhesin PIA [16], in all clinical 
isolates (Figure 2b). 
 
Figure 2. Biofilm formation of clinical LA-MRSA, HA-MRSA, and MSSA CF isolates in BHIG and 
microarray analysis of biofilm-associated virulence genes. (a) Bacterial overnight cultures were 
diluted in fresh BHIG, transferred into a 96-well plate and incubated at 37 °C to allow biofilm 
formation. After 24 h, the biofilms were washed, stained with crystal violet, solubilized with 
ethanol/acetone, and absorbance was measured at OD655 nm with a microplate reader. As a negative 
control, Staphylococcus carnosus TM300, and as a positive control, Staphylococcus epidermidis RP62A, 
were used. Data represent the mean of at least five biological replicates ± SD, analyzed in four to eight 
technical repetitions. Statistical analysis was done by applying one-way ANOVA, followed by 
Bonferroni’s post hoc test for multiple comparisons (*** p ≤ 0.001). To keep the graph clear, only 
particular significances are displayed. (b) Microarray was performed according to the manufacturer’s 
instructions (Alere Technologies GmbH [now Abbott Rapid Diagnostics GmbH, Jena, Germany]). 
Dark gray squares indicate genes that were detected. Abbreviations: ANOVA (analysis of variance), 
BHIG (brain heart infusion supplemented with 0.25% glucose), HA-MRSA (hospital-associated 
methicillin-resistant S. aureus), icaA/C/D (intercellular adhesion protein A/C/D), LA-MRSA (livestock-
associated methicillin-resistant S. aureus), MSSA (methicillin-susceptible S. aureus), NC (negative 
control), PC (positive control), S (isolated from sputum), SD (standard deviation), spa (staphylococcal 
protein A), T (isolated from throat). 
2.3. LA-MRSA Invade Airway Epithelial Cells and are Cytotoxic 
To determine the invasiveness and cytotoxicity of LA-MRSA, HA-MRSA, and MSSA clinical CF 
isolates towards host cells, we infected A549 airways epithelial cells and measured the number of 
intracellularly located bacteria 2 h post infection and the release of lactate dehydrogenase (LDH) from 
A549 cells, which is released upon necrosis [27], 24 h post infection. Only the late isolates of LA-
MRSA t034T and HA-MRSA t010 were significantly more invasive in A549 cells than their respective 
early isolates and the highly invasive control strain Cowan I (Figure 3a). All other isolates were either 
equally or less invasive compared to the control strain. Nevertheless, of all the analyzed isolates, the 
MSSA strains demonstrated the lowest invasiveness. Surprisingly, this group harbored the highest 
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number of cytotoxic strains (Figure 4a). In more detail, the cytotoxicity assay revealed that four MSSA 
strains (spa-types t617 and t080), three LA-MRSA strains (early and late LA-MRSA t034S and late LA-
MRSA t034T), but only one HA-MRSA strain (late HA-MRSA t003), provoked LDH release from A549 
cells 24 h post infection. 
By microarray analysis, we detected a similar pattern of adhesion-, invasion-, and cytotoxicity-
associated genes in all isolates, independent of their ability to invade or lyse host cells (Figures 3b 
and 4b). However, in contrast to all HA-MRSA and some MSSA strains, all LA-MRSA isolates 
harbored the collagen adhesin gene cna, but were negative for fib and sasG encoding for fibrinogen-
binding protein and surface protein G (Figure 3b) and the cytotoxicity-associated enterotoxin, 
leukocidin, exotoxin, and serine protease genes egc, lukD/E, seg/i/lm/ln/lo/lu, setB2/B3, and splA/B 
(Figure 4b). 
 
Figure 3. Invasion of clinical LA-MRSA, HA-MRSA, and MSSA CF isolates into A549 airway epithelial 
cells and microarray analysis of adhesion and invasion-associated virulence genes. (a) Epithelial lung 
cells were infected with mid-logarithmic S. aureus from glycerol stocks and incubated for 2 h, followed 
by the eradication of extracellular bacteria. Cells were lysed in water and intracellular bacteria were 
plated on agar to determine the number of internalized bacteria by counting CFU. The percentage of 
invasive bacteria was calculated by dividing CFU/mL of internalized bacteria by CFU/mL of the 
inoculum used for infection. As a control, the highly invasive S. aureus strain Cowan I was used. Data 
represent the mean of at least four biological replicates ± SD, analyzed in technical duplicates. 
Statistical analysis was done by applying one-way ANOVA, followed by Bonferroni’s post hoc test 
for multiple comparisons (*** p ≤ 0.001). To keep the graph clear, only particular significances are 
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displayed. (b) Microarray was performed according to the manufacturer’s instructions (Alere 
Technologies GmbH [now Abbott Rapid Diagnostics GmbH, Jena, Germany]). While dark gray 
squares indicate the genes that were detected, white squares mark undetected genes. Abbreviations: 
ANOVA (analysis of variance), bap (biofilm-associated protein), CFU (colony forming units), clfA/B 
(clumping factor A/B), cna (collagen adhesin), coA (staphylocoagulase), ebh (extracellular matrix-
binding protein), ebpS (elastin-binding protein), eno (enolase), fib (fibrinogen-binding protein), fnbA/B 
(fibronectin-binding protein A/B), HA-MRSA (hospital-associated methicillin-resistant S. aureus), 
isdA (iron-regulated surface determinant protein), LA-MRSA (livestock-associated methicillin-
resistant S. aureus), map (MHC class II analog protein), MSSA (methicillin-susceptible S. aureus), 
plsSCC (plasmin-sensitive surface protein encoded on staphylococcal cassette chromosome), S 
(isolated from sputum), sasG (surface protein G), SD (standard deviation), sdrC/D (serine-aspartate 
repeat-containing protein C/D), spa (staphylococcal protein A), T (isolated from throat), vwb (von 
Willebrand factor-binding protein). 
 
Figure 4. Cytotoxic effect of clinical LA-MRSA, HA-MRSA, and MSSA CF isolates on A549 airway 
epithelial cells and microarray analysis of cytotoxicity-associated virulence genes. (a) The cytotoxic 
effect of intracellular bacteria was assessed by measuring the amount of released LDH in the culture 
supernatant of A549 cells 24 h post infection following the instructions of the CytoTox® non-
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radioactive cytotoxicity assay kit (Promega, Walldorf, Germany). As a negative control, the 
supernatant of A549 cells treated with RPMI medium supplemented with 20% glycerin, and as a 
positive control, supernatant of A549 cells treated with 0.09% Triton X-100, were used (the latter one 
applied in 1:10 dilution). The percentage of the cytotoxicity of the bacterial strains and negative 
control was calculated with regard to the positive control, which was set to 100%. Data represent the 
mean of three biological replicates ± SD, analyzed in technical duplicates. Statistical analysis was done 
by applying one-way ANOVA, followed by Bonferroni’s post hoc test for multiple comparisons (* p 
≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001). To keep the graph clear, only particular significances are displayed. 
(b) Microarray was performed according to the manufacturer’s instructions (Alere Technologies 
GmbH [now Abbott Rapid Diagnostics GmbH, Jena, Germany]). While dark gray squares indicate 
genes that were detected, white squares mark negative results. Light gray squares represent genes 
whose presence was not determined. Abbreviations: ANOVA (analysis of variance), aur (aureolysin), 
CFU (colony forming units), edinA/B/C (epidermal cell differentiation inhibitor A/B/C), egc 
(enterotoxin gene cluster), etA/B/D (exfoliative toxin A/B/D), lukD/E/FM/S/X/Y (leukocidin 
D/E/F/M/S/X/Y), lukF/S-PV (Panton-Valentine leukocidin F/S), HA-MRSA (hospital-associated 
methicillin-resistant S. aureus), LA-MRSA (livestock-associated methicillin-resistant S. aureus), LDH 
(lactate dehydrogenase), NC (negative control), nuc1 (thermonuclease), MSSA (methicillin-
susceptible S. aureus), S (isolated from sputum), saeS (histidine protein kinase of two-component 
regulatory system saeR/S), sarA (staphylococcal accessory regulator A), 
sea/b/c/d/e/g/h//j/k/l/lm/ln/lo/lu/q/r (staphylococcal enterotoxin a/b/c/d/e/g/h//j/k/l/lm/ln/lo/lu/q/r), 
setB1/B2/B3 (staphylococcal exotoxin), SD (standard deviation), spa (staphylococcal protein A), 
splA/B/E (serine protease A/B/E), sspA (serine protease), sspB/P (staphopain B/A), T (isolated from 
throat), tst1 (toxic shock syndrome toxin 1). 
2.4. LA-MRSA are Tetracycline-Resistant 
The presence of specific resistance genes in LA-MRSA, HA-MRSA, and MSSA clinical CF isolates 
was determined by microarray analysis. As expected, LA- and HA-MRSA carried more resistance 
genes than MSSA (Table 2). Nearly all analyzed bacterial strains harbored the bla-operon conferring 
penicillin resistance, but only LA- and HA-MRSA were positive for the β-lactam resistance gene 
mecA. In addition, most LA- and HA-MRSA isolates, but only two MSSA strains, possessed the 
erythromycin and clindamycin resistance gene ermA. Interestingly, while fosB (fosfomycin resistance 
gene) was detectable in all HA-MRSA and most MSSA, tetM and tetK (tetracycline resistance genes) 
were exclusively found in LA-MRSA. Importantly, in the late isolate of MSSA t080, the genes aacA-
aphD (gentamicin, tobramycin, and kanamycin resistance) and dfrS1 (trimethoprim resistance) were 
not present, although we identified them in the corresponding early isolate, indicating a loss of the 
resistance genes in the course of adaptation to the host. Additionally, in the late isolate of LA-MRSA 
t034T and LA-MRSA t011, the genes for aadD (kanamycin resistance) and ermC (erythromycin 
resistance) were lost during persistence, respectively. In contrast, the genes aphA3, cat, cfr, fexA, inuA, 
mefA, mphC, msrA, mupA, vanA/B/Z, vatA/B, and vgaA conferring resistance to aminoglycosides, 
phenicol antibiotics, lincosamides, macrolides, mupirocin, glycopeptides, and streptogramins, 
respectively, were not detected at all in any of the analyzed bacterial strains.
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Table 2. Subset of resistance genes detected in LA-MRSA, HA-MRSA, and MSSA CF isolates by microarray analysis. Microarray was performed according to 
the manufacturer’s instructions (Alere Technologies GmbH [now Abbott Rapid Diagnostics GmbH, Jena, Germany]). 
 LA-MRSA HA-MRSA MSSA 
spa-type t034S t034T t011 t003 t010 t548 t617 t080 t002 
 Isolate 
Gene Early Late Early Late Early Late Early Late Early Late Early Late Early Late Early Late Early Late 
aacA-
aphD                   
aadD                   
aphA3                   
blaI/R/Z                   
cat                   
cfr                   
dfrS1                   
ermA                   
ermB                   
ermC                   
fexA                   
fosB                   
inuA                   
mecA                   
mefA                   
mphC                   
msrA                   
mupA                   
tetK                   
tetM                   
vanA/B/Z                   
vatA/B                   
vgaA                   
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Abbreviations: aacA-aphD (bifunctional 6'-aminoglycoside N-acetyltransferase AAC(6’)-2’’-aminoglycoside phosphotransferase APH(2’’); resistance to gentamicin, 
tobramycin, and kanamycin), aadD (aminoglycoside adenyltransferase; resistance to kanamycin), aphA3 (3'-aminoglycoside phosphotransferase type III; resistance to 
kanamycin), blaI/R/Z (β-lactamase repressor, regulator, and gene; resistance to penicillin), cat (chloramphenicol acetyltransferase; resistance to chloramphenicol), cfr (rRNA 
methyltransferase; resistance to linezolid, chloramphenicol, florfenicol, and clindamycin), dfrS1 (resistance to trimethoprim), ermA/B/C (rRNA adenine N(6)-
methyltransferases; resistance to erythromycin and clindamycin), fexA (chloramphenicol exporter; resistance to florfenicol and chloramphenicol), fosB (metallothiol 
transferase; resistance to fosfomycin), HA-MRSA (hospital-associated methicillin-resistant S. aureus), inuA (resistance to lincosamides), LA-MRSA (livestock-associated 
methicillin-resistant S. aureus), mecA (penicillin binding protein 2a; resistance to β-lactam antibiotics, like methicillin), mefA (macrolide efflux protein A; resistance to 
macrolides), mphC (macrolide phosphotransferase; resistance to macrolides), msrA (ribosomal protection protein; resistance to erythromycin and streptogramin), MSSA 
(methicillin-susceptible S. aureus), mupA (isoleucyl-tRNA synthetase; resistance to mupirocin), S (isolated from sputum), T (isolated from throat), tetK/M (tetK: tetracycline 
efflux protein/tetM: ribosomal protection protein; resistance to tetracycline), vanA/B/Z (glycopeptide resistance proteins; resistance to vancomycin), vatA/B 
(acetyltransferases; resistance to streptogramins), vgaA (ribosomal protection protein; resistance to streptogramins). Dark gray squares: positive, light gray squares: not 
determined, white squares: negative.
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3. Discussion 
To the best of our knowledge, this is the first study that analyzed the virulence and adaptation 
of LA-MRSA infecting the respiratory tract of CF patients. The study was performed in the Münster 
region, an area with a high pig-farming density and known as a hotspot of LA-MRSA in Germany 
[28,29]. LA-MRSA CF isolates were examined in comparison to HA-MRSA and MSSA CF isolates 
regarding their hemolytic activity, biofilm formation, invasion in airway epithelial cells, cytotoxicity, 
and resistance genes. 
Our hemolysis assay revealed that LA-MRSA were significantly more hemolytic than HA-
MRSA and MSSA, which might be partly due to the fact that these clones belong to the agr-specificity 
group I. This is in accordance with the findings of Mairpady Shambat et al., who showed that S. aureus 
isolates of agr-type I had a higher hemolytic activity than S. aureus assigned to agrII and III [30]. 
Importantly, all LA-MRSA and only one HA-MRSA strain produced β-hemolysin. As these isolates 
were negative for sak, chps, and scin, genes that are encoded on a bacteriophage [17], it is highly likely 
that they lost this phage in the course of bacterial adaptation to the animal host, in which genes which 
provide protection against the human host defense, are not required and are dispensable [10], while 
a loss during chronic airway infection of the respective CF patient is less likely in these LA-MRSA 
isolates [31]. However, as for other human patient populations, bacteriophage phi3 acquisition 
seemed to be no major driver for the re-adaptation of LA-MRSA to the human host [32]. 
All LA-MRSA in our study could be assigned to CC398 and spa-types t011 and t034, which are 
the major LA-MRSA-associated spa-types recovered from farm animals, companion animals, and 
humans in Germany and Europe in general [33–35]. Interestingly, two other research groups isolated 
LA-MRSA of the same clonal complex and spa-types from CF airways, which also did not carry the 
bacteriophage-associated genes sak, chps, and scin either [22,24]. In our study, we also analyzed 
persisting LA-MRSA isolates, which resided in the airways of the individual CF patients for three, 
four, and eight years. Unexpectedly, these LA-MRSA isolates did not pick up the bacteriophage, 
which confers protection against host defense, and which could have been potentially transferred by 
co-colonizing S. aureus strains. 
Similar to HA-MRSA and MSSA, LA-MRSA were weak biofilm formers. Therefore, we assume 
that biofilm production is not associated with the sole presence of specific biofilm- or adhesion-
associated genes like icaADC, clfA/B (clumping factor A/B), fnbA/B (fibronectin-binding protein A/B), 
sasG, and sdrC/D (serine-aspartate repeat-containing protein C/D) [19,36]. Different regulatory 
mechanisms might induce or repress biofilm formation in the investigated bacterial isolates. 
Furthermore, the biofilm production of MRSA is heavily influenced by environmental factors, which 
strongly differ between in vitro and in vivo experiments and might cause the conversion of in vivo 
biofilm formers to in vitro non-biofilm formers [37]. Thus, in vivo biofilm experiments should be 
done to investigate the biofilm production of the S. aureus CF isolates in more detail. 
A previous study with porcine and non-CF human LA-MRSA revealed a high cytotoxic potential 
comparable to certain CA-MRSA [38]. Here, in interaction studies with airway epithelial cells, LA- 
and HA-MRSA tended to be more invasive than MSSA. Surprisingly, LA-MRSA and MSSA strains 
were especially cytotoxic and caused LDH release from airway epithelial cells, indicating that not 
only high, but also low, numbers of intracellular bacteria can induce host cell necrosis. Interestingly, 
while the adhesion- and invasion-associated gene cluster was similar among LA-MRSA and MSSA, 
only LA-MRSA lacked toxin and protease genes important for infections in humans. However, 
invasive and cytotoxic bacteria harbored the same adhesion-, invasion-, and cytotoxicity-associated 
genes as non-invasive and non-cytotoxic strains, indicating that these genes can, but not necessarily 
must, support the bacterial invasion and lysis of host cells. To further study these effects, gene 
expression analysis will be helpful to determine if differences in transcription might cause the 
respective phenotype. In addition, the investigation of virulence regulators such as sigma factor B 
(sigB), staphylococcal accessory regulator A (sarA), and agr or genes of the bacterial stress response, 
like superoxide dismutases sodA and sodM, or the caseinolytic protease clpC, which were shown to 
be involved in intracellular survival and long-term persistence of S. aureus in non-professional 
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phagocytes [39–42], could be helpful to explore the different invasion and cytotoxicity traits of the 
bacterial CF isolates.  
As expected, the microarray analysis verified the presence of the methicillin-resistance gene 
mecA in LA- and HA-MRSA [8]. Interestingly, tetM and tetK conferring resistance to tetracycline were 
exclusively found in LA-MRSA, which most likely represents bacterial adaptation to the specific 
antibiotic selective pressure in livestock animals [10] and might result from the addition of 
tetracycline to feedstuff with the aim of preventing and controlling infections in livestock [43]. 
Recently, a Brazilian and a Belgian group also isolated tetracycline-resistant LA-MRSA from the 
airways of CF patients [22,24]. However, resistance to this antibiotic is not essentially part of the LA-
MRSA resistance profile, as Garbacz et al. found an LA-MRSA CF isolate that was tetracycline-
susceptible [23]. The presence of all remaining antibiotic resistance genes mostly detected in MRSA, 
but sporadically also found in MSSA (aacA-aphD, aadD, blaI/R/Z, dfrS1, ermA/B/C, and fosB), most 
likely results from the application of tobramycin, kanamycin, penicillins, trimethoprim, 
erythromycin, and fosfomycin to CF patients or livestock animals. However, as the analyzed S. aureus 
strains are still sensitive to a lot of antibiotics commonly used in CF therapy or livestock infection 
prevention, like vancomycin, linezolid, chloramphenicol, clindamycin, lincomycin, mupirocin, 
streptogramins, and several macrolides [43,44], many therapeutic options to cure infections caused 
by these bacterial strains are still available. 
In addition to the direct comparison between LA-MRSA, HA-MRSA, and MSSA, we 
investigated differences between early and late S. aureus CF isolates and studied the bacterial 
adaptation mechanism facilitating long-term persistence in CF airways. We detected differences in 
the phenotypic characteristics of late, compared to early, isolates: Of the nine investigated early/late 
strain pairs, some late isolates were significantly more hemolytic (HA-MRSA t003 and t548) or less 
hemolytic (MSSA t002), more cytotoxic (LA-MRSA t034T), more invasive (LA-MRSA t034T and HA-
MRSA t010), produced more biofilm (LA-MRSA t034T and MSSA t080), and possessed fewer 
resistance genes (LA-MRSA t034T and t011 and MSSA t080) than their respective early counterparts. 
These findings reveal that changes in hemolysis, invasion, cytotoxicity, biofilm formation, and 
resistances can be associated with bacterial long-term persistence in CF airways, as also detected 
elsewhere [2,19,21,45]. Importantly, these adaptations were only detectable in a few isolates, 
indicating that S. aureus adaptation to CF airways is an individual, complex process that probably 
depends on various factors including host, treatment, co-infecting isolates, and the state of lung 
disease. 
Summarized, we demonstrated that LA-MRSA infecting CF airways are strongly hemolytic, 
cytotoxic, and invasive bacteria that possess a virulence potential similar or even higher than that of 
HA-MRSA. Furthermore, we confirmed that S. aureus individually adapts to the airways of CF 
patients, which eventually could impede the success of antistaphylococcal therapy of respiratory CF 
infections. 
4. Materials and Methods 
4.1. Ethical Statement 
An ethical approvement was obtained from the Ethical Committee in Münster, Westfalian 
Wilhelms University and Physicians Chamber Westfalen-Lippe, Germany (2018-466-f-S), approval 
date: 20 February 2019 Due to the retrospective study and anonymized patient data, no written 
informed consent was required.  
4.2. Bacterial Strains and Growth Conditions 
Clinical S. aureus strains were isolated from the sputum samples or throat swabs of nine 
chronically S. aureus-infected CF patients from the CF centers of the University Hospital Münster, 
Germany, and the Clemenshospital, Münster, Germany, and were processed as described recently 
[40]. Per patient, two clonal S. aureus isolates, an early and a late isolate, which carried the same spa-
type and MLST, were selected for analysis. While the early isolates were obtained soon after the onset 
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of staphylococcal airway infection, the late isolates were recovered three to 13 years later and 
represent persistent bacterial strains. Details about the investigated clinical S. aureus CF isolates are 
shown in Table 3. The laboratory strains S. aureus Cowan I, Staphylococcus epidermidis RP62A, and 
Staphylococcus carnosus TM300 were used as controls and are listed in Table 4. 
In general, bacterial glycerol stocks were subcultured on Columbia sheep blood agar (37 °C, 18–
24 h) and streaked onto fresh blood agar plates several days prior to the experiments. For the analysis 
of hemolysis, bacteria were cultivated overnight for 18 h at 37 °C and 160 rpm in Tryptic Soy Broth 
(TSB) under aerated conditions, centrifuged at 45,000 rpm for 5 min and sterile filtered using a 0.22 
µm filter. For the determination of biofilm formation, bacteria were grown in brain heart infusion 
supplemented with 0.25% glucose (BHIG) at 37 °C at 160 rpm under aerated conditions. For the 
infection of airway epithelial cells with the subsequent determination of bacterial invasion and 
cytotoxicity, glycerol stocks were used, generated as follows: starting from a bacterial overnight 
culture in TSB, 10 mL of TSB in a 100 mL baffled flask were set to an OD578 nm of 0.1 and cultivated at 
37 °C and 160 rpm until mid-logarithmic growth phase. Using this culture, 5 mL of phosphate-
buffered saline (PBS) were inoculated to an OD578 nm of 1 and centrifuged at 4500 rpm for 7 min. 
Subsequently, the bacterial pellet was resuspended in RPMI-1640 (R7388, Sigma-Aldrich [now Merck 
kGaA, Darmstadt, Germany]) medium supplemented with 2 mg/mL NaHCO3 (Sigma-Aldrich [now 
Merck kGaA, Darmstadt, Germany]) and treated with a sonifier in order to separate cell clumps. 
Afterwards, glycerol was added to generate a 20% working solution, serially diluted in PBS, plated 
on blood agar, and incubated over night at 37 °C to determine colony forming units (CFU) the next 
day. Glycerol stocks were stored at −20 °C until usage. 
Table 3. Early and late S. aureus CF isolates analyzed in the study. 
Strain Patient Isolate MLST spa-type spa-type Repeats Origin Year of 
Isolation 
LA-
MRSA 
1 
Early 
CC398 t034 08-16-02-25-02-25-34-24-25 Sputum 
2014 
Late 2017 
2 
Early 
CC398 t034 08-16-02-25-02-25-34-24-25 Throat 
2002 
Late 2010 
3 
Early 
CC398 t011 08-16-02-25-34-24-25 Sputum 
2012 
Late 2016 
HA-
MRSA 
4 
Early 
CC5 t003 26-17-20-17-12-17-17-16 Sputum 
2010 
Late 2016 
5 
Early 
CC5 t010 26-17-34-17-20-17-12-17-16 Sputum 
2013 
Late 2017 
6 
Early 
CC5 t548 26-23-17-34-17-20-17-12-16 Throat 
2008 
Late 2014 
MSSA 
7 
Early 
CC30 t617 15-21-16-02-24-24 
Throat 2001 
Late Sputum 2010 
8 
Early 
CC45 t080 09-02-16-34-42-17-16-34 Throat 
1995 
Late 2008 
9 
Early 
CC5 t002 26-23-17-34-17-20-17-12-17-16 Sputum 
1994 
Late 1997 
Abbreviations: CC (clonal complex), HA-MRSA (hospital-associated methicillin-resistant S. aureus), 
LA-MRSA (livestock-associated methicillin-resistant S. aureus), MLST (multilocus sequence type), 
MSSA (methicillin-susceptible S. aureus), S (isolated from sputum), spa (staphylococcal protein A), T 
(isolated from throat). 
Table 4. Bacterial laboratory and reference strains used in the study. 
Bacterial species Strain Application Reference 
Staphylococcus aureus Cowan I Invasion assay (PC) ATCC 12598 
Staphylococcus carnosus TM300 Biofilm assay (NC) [46] 
Staphylococcus epidermidis RP62A Biofilm assay (PC) ATCC 35984 
Abbreviations: NC (negative control), PC (positive control). 
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4.3. spa-Typing 
Staphylococcal DNA was isolated with the DNeasy Blood & Tissue Kit (Qiagen, Hilden, 
Germany), following the instructions of the manufacturer, with a lysostaphin (AMBI Products, 
Lawrence, NY, USA) step implemented at the beginning. The polymorphic region x of spa was 
amplified with the primers spa-forward (5’-TAAAGACGATCCTTCGGTGAGC-3’) and spa-reverse 
(5’-CAGCAGTAGTGCCGTTTGCTT-3’) and the REDTaq® ReadyMix™ (Sigma-Aldrich [now Merck 
kGaA, Darmstadt, Germany]) via polymerase chain reaction (PCR), applying the following program 
on a thermocycler (Bio-Rad Laboratories GmbH, Feldkirchen, Germany): 1 min 95 °C, 30 s 95 °C + 30 
s 60 °C + 30 s 72 °C (35 repetitions), 3 min 72 °C. The PCR product was purified using the QIAquick 
PCR Purification Kit (Qiagen, Hilden, Germany) and sequenced by Eurofins Genomics (Ebersberg, 
Germany). The spa-types were identified using the software Ridom® StaphType (Ridom GmbH, 
Münster, Germany). The spa-type repeats are listed in Table 3. 
4.4. Microarray Analysis 
Staphylococcal DNA was isolated as described for spa-typing. However, instead of lysostaphin, 
components A1 and A2 of the S. aureus Genotyping Kit 2.0 (Alere Technologies GmbH [now Abbott 
Rapid Diagnostics GmbH, Jena, Germany]) were applied to lyse bacteria. Subsequently, microarrays 
were prepared according to the instructions of the S. aureus Genotyping Kit 2.0 and analyzed using 
the ArrayMate™ Reader (Alere Technologies GmbH [now Abbott Rapid Diagnostics GmbH, Jena, 
Germany]), running with the following program: 5 min 96 °C, 60 s 96 °C + 20 s 50 °C + 40 s 72 °C (55 
repetitions). The results of all analyzed genes are listed in Supplementary Table S1. 
4.5. Hemolysis Assay 
4.5.1. Macroscopic Evaluation 
Bacteria were streaked onto Columbia sheep blood agar, incubated at 37 °C, and subsequently 4 
°C, for 24 h, to determine the activity of bacterial hemolysins. Pictures were taken with a digital 
camera and cropped using IrfanView (Irfan Skiljan, Wiener Neustadt, Austria). Colony sizes of the 
isolates might differ due to variable camera positions and therefore, cannot be compared among each 
other. As determination of hemolysis, but not colony size, was focus of the investigation, colony size 
was not measured.  
4.5.2. Photometrical Quantification 
Photometrical quantification of bacterial hemolytic activity was assessed by incubating rabbit 
erythrocytes with sterile filtered supernatants of bacteria grown overnight in TSB and measuring the 
absorbance of hemoglobin released from damaged erythrocytes. Briefly, 100 µl of sterile filtered 
supernatants of bacterial overnight cultures in TSB were added to the wells of a 96-well plate (u-
bottom) and diluted in a 1% bovine serum albumin (BSA)/PBS solution in 1:2 steps. Subsequently, 
100 µl of a 2% rabbit erythrocyte solution generated from rabbit whole blood (Fiebig 
Nährstofftechnik, Idstein, Germany), which was three times centrifuged at 3000 rpm for 10 min at 4 
°C, resuspended in 1% BSA/PBS solution, and finally diluted 1:50 in 1% BSA/PBS solution, were 
added to each well and mixed gently by pipetting up and down. The plate was incubated for 1 h at 
37 °C to allow the lysis of erythrocytes and centrifuged for 10 min at 2000 rpm at room temperature. 
One hundred microliters of the supernatant were transferred into a new 96-well plate and the 
absorbance of hemoglobin released from damaged erythrocytes was measured at OD450 nm with a 
microplate reader (Bio-Rad Laboratories GmbH, Feldkirchen, Germany). As a negative control, 
untreated 2% erythrocyte solution, and as a positive control, 2% erythrocyte solution treated for 1 h 
with 4.5% Triton X-100, was used. To compare the hemolytic effect of the different S. aureus strains, 
the absorbance was plotted against the dilution steps (step 0 = undiluted, step 1 = two-fold dilution, 
step 2 = four-fold dilution, step 3 = eight-fold dilution, step 4 = 16-fold dilution, step 5 = 32-fold 
dilution, step 6 = 64-fold dilution, step 7 = 128-fold dilution, step 8 = 256-fold dilution, step 9 = 512-
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fold dilution) and the mean effective dilution ED50 (the dilution step at which 50% of all erythrocytes 
are lysed) was calculated using the linear slope of the inflection point of the hemolysis graph. The 
higher the ED50, the stronger the hemolytic effect. 
4.6. Biofilm Assay 
Bacterial biofilm formation was investigated as described by Schwartbeck et al. [19], with some 
modifications. Briefly, bacterial overnight cultures in BHIG were used to inoculate 2 mL of fresh 
BHIG to an OD578 nm of 0.02. Of this solution, 200 µL were added to the wells of a 96-well plate 
(Greiner Bio One, Frickenhausen, Germany) and incubated for 24 h at 37 °C in a metal box lined with 
wet paper towels to prevent dehydration. Subsequently, the plates were washed three times with 200 
µl PBS/well and the biofilms were stained with 0.1% crystal violet for 15 min at room temperature. 
After three further washing steps, 100 µl ethanol/acetone (80:20) were added to each well to solubilize 
the biofilms and the absorbance was detected at 655 nm with a microplate reader (Bio-Rad 
Laboratories GmbH, Feldkirchen, Germany). As a negative control, S. carnosus TM300, and as a 
positive control, S. epidermidis RP62A, were used. 
4.7. Cell Culture Infection Model 
We performed infection assays using A549 airway epithelial cells (ATCC® CCL-185™). The cells 
were cultivated and infected as described recently [40], with some modifications. Briefly, the cells 
were seeded in 75 cm2 cell culture flasks (Greiner Bio-One, Frickenhausen, Germany) and cultivated 
in RPMI-1640 (R7388, Sigma-Aldrich [now Merck kGaA, Darmstadt, Germany]) medium, 
supplemented with 2 mg/mL NaHCO3 (Sigma-Aldrich [now Merck kGaA, Darmstadt, Germany]) 
and 10% fetal bovine serum (FBS) (Biochrom GmbH [now Merck kGaA, Darmstadt, Germany]) at 37 
°C and 5% CO2. The medium was changed at least every third day and the cells were split depending 
on their density. The detachment of confluent cells was achieved by 15 min of incubation with 
Trypsin/EDTA (PAA Laboratories [now Fisher Scientific GmbH, Schwerte, Germany]). 
For the invasion assay, three days prior to the experiments, A549 cells were seeded in 12-well 
plates (Corning GmbH, Wiesbaden, Germany) at a density of 40,000 cells/cm2 and cultivated to 
confluence. For each experiment, one additional well was covered with cells, which was used to 
determine the cell number on the day of the experiment, when the cells were washed with PBS 
(D8537, Sigma-Aldrich [now Merck kGaA, Darmstadt, Germany]) and covered with invasion 
medium, consisting of RPMI supplemented with 2 mg/mL NaHCO3 and 10 mg/ml human serum 
albumin (HSA) (Kedrion Biopharma, Gräfelfing, Germany). Subsequently, the host cells were 
infected with mid-logarithmic S. aureus from glycerol stocks, using a multiplicity of infection (MOI) 
of 100, and incubated at room temperature for 15 min to allow the sedimentation of bacteria. 
Eukaryotic and prokaryotic cells were incubated at 37 °C and 5% CO2. To determine the inoculum 
used for infection, the bacterial glycerol stocks were serial diluted in PBS, plated on blood agar, and 
incubated overnight at 37 °C to determine the CFU the next day. After 2 h of incubation, cells were 
washed two times with PBS and extracellular bacteria were killed by the incubation of cells for 30 
min with RPMI medium supplemented with 2 mg/mL NaHCO3 and 20 µg/mL lysostaphin. 
Supernatants of the killing step were plated on agar to control the toxic effect of lysostaphin. After 
applying two further washing steps, cells were lysed in water to release the intracellular bacteria. Cell 
lysates were pipetted through a syringe, serially diluted in PBS, and plated on blood agar to 
determine the CFU/mL of intracellular bacteria after 24 h of incubation at 37 °C. As control, the highly 
invasive S. aureus strain Cowan I was used. 
4.8. Cytotoxicity Assay 
To analyze the cytotoxicity of intracellular bacteria, A549 cells were infected and treated as 
described for the invasion assay. However, after lysostaphin treatment, cells were washed and 
covered with RPMI medium supplemented with 2 mg/mL NaHCO3, 10% FBS, 1% 
antibiotic/antimycotic solution, and 2% MycoKill AB and incubated for up to 24 h at 37 °C and 5% 
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CO2. Subsequently, 500 µL of culture supernatant were drawn from the well plate, centrifuged at 
5000 rpm for 5 min and used to determine the bacterial cytotoxicity by measuring the activity of LDH 
with the CytoTox® non-radioactive cytotoxicity assay kit (Promega, Walldorf, Germany), following 
the manufacturer’s instructions. The higher the absorbance, the higher the LDH release from A549 
cells and the bacterial cytotoxicity. As a negative control, the supernatant of A549 cells treated with 
10 µL RPMI medium supplemented with 20% glycerin, and as a positive control, the supernatant of 
A549 cells treated with 0.09% Triton X-100, were used (the latter one applied in a 1:10 dilution). 
4.9. Statistical Analysis 
Statistical analysis was done by applying one-way analysis of variance (ANOVA) with 
subsequent Bonferroni’s post hoc tests for multiple comparisons (p-value * ≤ 0.05, p-value ** ≤ 0.01, p-
value *** ≤ 0.001) using the software GraphPad Prism 5 (GraphPad Software, San Diego, CA, USA). 
Only the most important significant differences are indicated in the figures. 
Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/12/6/360/s1, Figure 
S1: Hemolysis assay on Columbia sheep blood agar, Table S1: Microarray results.  
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